Axon shares dropped 20% after reporting a Q3 profit miss tied to tariff costs, though revenue exceeded forecasts at $710.6 ...

Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as ...

McDonald's Q3 2025 results showed a 3.6% rise in global sales, while EPS of $3.18 came in just below forecasts.

Emerson’s Q4 2025 results showed steady growth, with EPS meeting expectations and revenue slightly below estimates.

Humana’s third-quarter results beat expectations with adjusted EPS of $3.24 and revenue of $32.65 billion, as the company ...